Key result
Trimetazidine improves NYHA class and boosts EF by ~7% over conventional therapy in heart failure.
Why the study?
Previous small studies suggested trimetazidine might preserve left ventricular function and control symptoms in post-ischemic HF, but its long-term effects on functional class, exercise tolerance, and LV function needed assessment.
Does the addition of trimetazidine to conventional therapy improve functional class and left ventricular function in patients with heart failure?
Comparison
Conventional therapy plus trimetazidine (20 mg three times daily) vs conventional therapy alone
Design
Open-label randomized trial
Follow-up
Mean 13 +/- 3 months
Authors
Loading...
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Current evidence supports the potential role of trimetazidine in HFrEF, but this is based on multiple smaller trials of varying quality in study design. We recommend a large pragmatic randomised clinical trial to establish the definitive role of trimetazidine in the management of HFrEF.”
“Trimetazidine in HFrEF was found to significantly reduce cardiovascular mortality (OR 0.33, 95% CI 0.21 to 0.53) and HF hospitalisations (OR 0.42, 95% CI 0.29 to 0.60). In addition, trimetazidine improved (New York Heart Association) functional class (mean difference: -0.44 (95% CI -0.49 to -0.39), 6 min walk distance (mean difference: +109 m (95% CI 105 to 114 m) and quality of life (standardised mean difference: +0.52 (95% CI 0.32 to 0.71).”
Supports trimetazidine in HF for LVEF and symptom gains; confirms metabolic modulation benefits in RCT evidence.
RCT (n=55)
Open-label
randomly allocated
Does the addition of trimetazidine to conventional therapy improve functional class and left ventricular function in patients with heart failure?
Absolute Event Rate: 43% vs 34%
p-value: p=0.002
The long-term addition of trimetazidine to standard heart failure therapy significantly improves left ventricular ejection fraction and functional class.
Fragasso et al. (2006) conducted an RCT in Heart failure (HF) (n=55). Trimetazidine vs. Conventional therapy alone was evaluated on Ejection fraction (EF) (p=0.002). Trimetazidine added to conventional therapy in heart failure patients significantly improved NYHA functional class (p<0.0001) and increased ejection fraction from 36% to 43% (p=0.002).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: